Performance & Vitality · Reviewed by Ian K. Tseng, MD

What Is MOTS-c? The Mitochondrial-Derived Peptide

MOTS-c belongs to a genuinely unusual category: peptides encoded not in the DNA of the cell nucleus but in the separate, much smaller genome carried inside mitochondria. That origin is what makes it scientifically interesting. It is also a compound where the honest description of the evidence is "early," and we would rather say so than not.

Published August 4, 2026 · Medical review by Ian K. Tseng, MD, Medical Director

Soothe IV Med Spa branded amber pharmacy vial on warm marble, representing the performance & vitality category of physician-supervised peptide therapy

The short answer

MOTS-c — mitochondrial open reading frame of the twelve-S ribosomal RNA type-c — is a sixteen-amino-acid peptide encoded within mitochondrial DNA rather than nuclear DNA. Research has examined its role in metabolic regulation, including activation of the AMPK pathway, and it has been described in the literature as an exercise-responsive peptide. The evidence base is predominantly preclinical with limited human data.

A peptide from the other genome

Nearly all human proteins are encoded in nuclear DNA. Mitochondria, however, retain their own small circular genome — a remnant of their ancestral origin as independent organisms — encoding a handful of genes essential to energy production.

MOTS-c was identified within a short open reading frame in the mitochondrial 12S ribosomal RNA gene. That places it in a small class of mitochondrial-derived peptides, molecules the cell produces from the mitochondrial genome that appear to act as signals communicating mitochondrial status to the rest of the cell and, potentially, the rest of the body.

The conceptual appeal is straightforward: if mitochondrial function underlies much of what people describe as energy, endurance, and metabolic health, a signaling molecule originating inside the mitochondria is a plausible place to look.

What the research examines

The most-cited mechanistic finding is that MOTS-c appears to influence the AMPK pathway. AMPK functions roughly as a cellular energy sensor — it is activated when cellular energy is low and shifts metabolism toward energy production and away from storage. It is also the pathway activated by exercise and by certain established metabolic medications.

Additional research has examined MOTS-c in the context of insulin sensitivity, glucose metabolism, and adipose tissue in animal models. Some human observational work has examined circulating MOTS-c levels in relation to exercise and metabolic status.

It has been characterized in parts of the literature as an "exercise mimetic," which is a phrase worth handling carefully. It describes an observed overlap in signaling pathways. It does not establish that administering the peptide reproduces the clinical benefits of exercise in humans, and it should not be read that way.

Being honest about the evidence stage

We would rather be plain about this than let enthusiasm do the talking. The MOTS-c evidence base consists largely of preclinical work — cell culture and animal models — plus observational human studies measuring endogenous levels. Large controlled trials of administered MOTS-c establishing clinical outcomes in humans are not currently a feature of the literature.

That is a reason for measured expectations, not a reason to dismiss the compound. Early is not the same as disproven. But a program that tells you a compound is well-established when it is not has told you something about its own credibility.

If you want the general framework for evaluating claims in this space, our article on whether peptides are safe covers how to read the difference between mechanism and demonstrated outcome.

How it is evaluated clinically

As with everything in the program, whether MOTS-c is appropriate for a given patient is a physician's determination made after a Good Faith Exam and bloodwork, with the evidence limitations above forming part of that conversation. Baseline metabolic markers — fasting glucose and insulin, hemoglobin A1c, lipids, comprehensive metabolic panel — establish the starting point and are monitored on the schedule your protocol sets.

Not everyone qualifies, and for some goals the appropriate recommendation is a different category of care entirely — including approaches like IV therapy where the goal is cellular support rather than a prescribed protocol.

Frequently asked questions

What makes MOTS-c different from other peptides?

It is encoded in mitochondrial DNA rather than nuclear DNA. Mitochondria retain a small circular genome separate from the cell nucleus, and MOTS-c was identified within a short open reading frame in the mitochondrial 12S ribosomal RNA gene. This places it in a small class of mitochondrial-derived peptides that appear to signal mitochondrial status to the wider cell.

What does MOTS-c do in the body?

The most-cited mechanistic finding is influence on the AMPK pathway, a cellular energy sensor activated when cellular energy is low that shifts metabolism toward energy production. Additional research has examined effects on insulin sensitivity, glucose metabolism, and adipose tissue, predominantly in animal models.

Is MOTS-c an exercise mimetic?

That phrase appears in the literature and describes an observed overlap in signaling pathways — MOTS-c influences AMPK, which is also activated by exercise. It does not establish that administering the peptide reproduces the clinical benefits of exercise in humans, and it should not be read that way.

How strong is the evidence for MOTS-c?

Early. The evidence base consists largely of preclinical cell culture and animal work, plus observational human studies measuring naturally occurring levels. Large controlled trials of administered MOTS-c establishing clinical outcomes in humans are not currently a feature of the literature. Early is not the same as disproven, but it warrants measured expectations.

Clinical references

Medically reviewed by Ian K. Tseng, MD, Medical Director of Soothe IV's peptide therapy program. The clinical statements in this article are supported by the following sources:

Lee C, Zeng J, Drew BG, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metabolism. 2015. pmc.ncbi.nlm.nih.gov
Reynolds JC, Lai RW, Woodhead JST, et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nature Communications. 2021. pmc.ncbi.nlm.nih.gov
U.S. Food & Drug Administration. Human Drug Compounding. www.fda.gov

Ready to talk to a physician?

Start your $50 Application — the comprehensive intake, physician Good Faith Examination, and medical clearance. A physician reviews your goals and labs and tells you honestly whether therapy is appropriate. Your fee credits in full toward your first month of membership. Available nationwide.

Book & Pay for Your $50 Application

Serving Orange County, Los Angeles, and San Diego — plus nationwide telehealth. All service areas.

This article is educational and is not medical advice. Statements have not been evaluated by the FDA. Peptide therapy is a physician-supervised medical service; specific protocols are determined individually after a Good Faith Examination and bloodwork, and not all applicants qualify. Some compounded medications used in physician-prescribed protocols are not FDA-approved. Data from clinical trials on FDA-approved medications should not be used to make assessments related to compounded medications. Soothe IV's peptide program is available nationwide via telehealth; prescriptions are issued by physicians licensed in your state.